
HGPS therapy with source-and-replace genome editing with liposome vector.

A group of genetic diseases caused by alterations of the **nuclear protein lamina A / C** and some related proteins.




 Hutchinson-Gilfordprogeria-syndrome





Negative
Consequences

- Hair Loss
- Osteoporosis
- Lipodystrophy
- Growth Delay
- Atherosclerosis
- Artheriosclerosis




Phenotype





Progerin is what makes the nucleus to be unstable.





OUR GOAL IS?

- Improve life expectancy;
- Reduce cardiovascular disease;
- Restablish wild type phenotype;
- Use of Non-invasive gene therapy;

HOW?

- Cardiovascular cells treatment by gene editing search-andreplace
- Cells Treatment in vitro as proof of concept and in vivo (mice);





Cardiac Cells

Experimental Protocol LCPE (Liposome Crispr Prime Editing) treatment


Liposome Vector + Crispr scearch and replace (bought assembled)



6

Intraperitoneal injection

Results in Vitro: Mice cells




	Liposome	Liposome+Crispr	Liposome+Crispr∆Cas9
In Vitro Cardiac Cells (Wt)	no changes	1x10^(-8) error cut	no changes
In Vitro Cardiac Cells (HGPS)	no changes	$1x10^{(-9)}$ error cut	no changes
In Vivo Cardiac Tissues (Wt)	no changes	$1x10^{(-12)}$ error cut	no changes
In Vivo Cardiac Tissues (HGPS)	no changes	1×10^{-14} error cut	no changes


Results in Vitro: Mice cells

(B) Representative immunohistochemical staining with anti-lamin A antibodies. Original magnification, ×400. Scale bar, 10 µm. Arrowhead, abnormality in the nuclear membrane.

В



(D) Western blot analysis to measure the expression of the C-terminal prelamin A and lamin A in WT and Zmpste24–/– MDSPCs, relative to the expression of β -actin or vinculin.



RFLP

Results in Vivo





ImmunoFluorescence of nuclear lamina.

It is evident a partial recovery of wild type phenotype with **LCPE** treatment.

9


cardiovascular tissues development






Significant QT interval prolungation = Higher risk of Ischemia

Results in Vivo



11



After LCPE treatment we observed restoration nuclear laminar of cardiovascular cells

Budget and Times

	Qt.	Inside storage	Outside storage
Mice Wt	20	4,8€ (one for die)	11,6€ (one for die)
Mice HGPS+	20	11,4€ (one for die)	16,8€ (one for die)
Mice HGPS+ .tr. LCPE	20	11,4€ (one for die	16,8€ (one for die)
Crispr Prime Kit	20	300€ (one Kit)	300€ (one Kit)
Staff	3+1	1500€x3 (Phd) + 2500€(post Phd)	1500€x3 (Phd) + 2500€(post Phd)
Liposome Kit	20	200€	200€
Various	/	10'000.00€	10'000.00€
cages for mice	60	8,80€ (one for die)	10,95€ (one for die)
Total	3 years	230'000.00€	250'000.00€

Crispr, In vivo liposome In vitro 3 To be 8 18 Research and months months Years research Continued protocol (mice) preparation

Pitfalls

• Possible oncogenic gene insertion

Solutions

- Sequencing
- Long term trials
- More efficient protocols

• High costs

http://dhajournals.org/journal/atvb http://biomodel.uah.es/en/lab/cybertory/analysis/trans.htm https://blast.ncbi.nlm.nih.gov/Blast.cgi https://www.nature.com/articles/nm1266 https://www.sciencedirect.com/science/article/pii/S0014482707001176 https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1399-0004.2005.00447.x https://onlinelibrary.wiley.com/doi/abs/10.1002/path.1655 https://www.nature.com/articles/nrg1906 https://europepmc.org/abstract/med/16550926 https://www.sciencedirect.com/science/article/pii/S0014482707001279 https://www.tandfonline.com/doi/abs/10.4161/nucl.21676